GAO Calls Out FDA Regulatory Backlog as Data System Flaws Delay 132K Reviews
A new Government Accountability Office report reveals the Food and Drug Administration faces a backlog of nearly 132,000 tobacco product applications, driven by legacy IT systems unable to track critical scientific review milestones and an average 507-day evaluation timeline.
The Food and Drug Administration (FDA) is struggling to manage a massive regulatory backlog, with nearly 132,000 tobacco product applications remaining unreviewed as of late 2025. Following a 2016 expansion of regulatory authority and a massive influx of more than 25 million submissions during 2020 and 2021, the agency's evaluation process has ground to a crawl. On average, the FDA required 507 days to complete an application review between CY2018 and CY2025, far missing established internal benchmarks that range from 7 to 180 days per phase.
According to a Government Accountability Office (GAO) audit, a key driver of the persistent delays is the FDA’s legacy data infrastructure. The agency’s internal data systems were not designed to collect or track granular milestone performance during the critical scientific evaluation phase. Without actionable operational telemetry, leadership lacks the performance insights required to measure progress, identify workflow bottlenecks, or enforce timeliness standards. While low-quality manufacturer submissions contributed to early screening delays, structural data tracking limitations remain the primary barrier to predictable processing.
For defense, government, and industry leaders, these findings highlight broader operational vulnerabilities across regulatory and procurement ecosystems. Defense enterprise health initiatives, military exchange systems, and commercial supply networks depend on legal clarity regarding off-the-shelf consumer goods, including nicotine delivery systems. Extended regulatory gridlock creates compliance uncertainty across base exchanges and commercial supply chains, exposing retail environments to illicit products while delaying lawful entries. Furthermore, the audit serves as a warning to federal acquisition authorities regarding the failure to align oversight mandates with modern data infrastructure.
To mitigate these issues, the FDA has issued updated technical guidance to improve submission quality and launched a September 2025 pilot program aimed at streamlining reviews for novel nicotine pouches. However, GAO emphasizes that until the agency upgrades its data architectures to capture stage-by-stage performance metrics, long-term operational efficiency will remain out of reach. Federal stakeholders across acquisition and regulatory compliance must prioritize end-to-end system visibility to ensure statutory execution and institutional accountability. (Source: GAO Reports)
Executive takeaway
Subscribe to receive signals like this — plus the executive analysis behind them.
Get the Signals